Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models

Figure 4

Src contributes to lapatinib resistance in breast cancer cells by interacting with EGFR rather than with HER2. (A) Western blot analysis of total cell lysates from MDA-MB-361, SKBR-3, MDA-MB-361-LR, and JIMT-1 human breast cancer cell lines transfected with an Src-specific siRNA (50 nM) and treated or not with lapatinib (1 μM). The siRNA-negative control consists of nontargeting sequences. (B) Immunoprecipitation using anti-HER2, anti-Src, and anti-EGFR antibodies and blotting with anti-EGFR, -HER2, -HER3, and -Src antibodies of MDA-MB-361, SKBR-3, MDA-MB-361-LR, and JIMT-1 human breast cancer cells grown in complete medium. Total lysate, not immunoprecipitated, from BT474 cells was used as positive control. (C) Western blot analysis of total cell lysates from MDA-MB-361, SKBR-3, MDA-MB-361LR, and JIMT-1 human breast cancer cell lines grown in complete medium. The relative optical density of phospho-protein levels normalized to the actin level is shown.

Back to article page